PRESS RELEASES

Date	Title
Mar 14, 2019	Ardelyx Appoints Renowned Nephrologist, Geoffrey A. Block, M.D., to Its Board of Directors
Mar 7, 2019	Ardelyx Announces Peer-Reviewed Publication of Positive Phase 3 Results of Tenapanor for the Treatment of Hyperphosphatemia in the Journal of the American Society of Nephrology
Mar 6, 2019	Ardelyx Reports Fourth Quarter 2018 Financial Results and Recent Highlights
Feb 21, 2019	Ardelyx to Participate in Leerink Partners 8th Annual Global Healthcare Conference
Feb 7, 2019	Ardelyx Collaboration Partner, Kyowa Hakko Kirin, Announces Initiation of a Phase 2 Clinical Study of Tenapanor for Hyperphosphatemia Patients on Dialysis in Japan
Nov 13, 2018	Ardelyx Announces FDA Acceptance of the Filing of its New Drug Application for Tenapanor for the Treatment of Patients with IBS-C
Nov 7, 2018	Ardelyx Reports Third Quarter 2018 Financial Results and Recent Highlights
Oct 26, 2018	Ardelyx Presents New Preclinical Data Demonstrating Synergy between Tenapanor and Sevelamer When Dosed in Combination for Elevated Serum Phosphorus
Oct 8, 2018	Ardelyx Showcases New Data from T3MPO-3 Long-Term Safety Trial of Tenapanor for IBS-C in Presidential Poster at ACG 2018 Annual Meeting
Oct 4, 2018	Ardelyx to Host Its First Annual Investor Day Focused on Treatment Landscape of Renal Disorders

FAQs

Email Alerts

Connect

Bay Area
34175 Ardenwood Boulevard
Fremont, CA 94555

Boston Area
200 West Street, 4th Floor
Waltham, MA 02451

Phone: 510.745.1700

Inquiries:
General: info@ardelyx.com
Media: media@ardelyx.com
Investor: investor@ardelyx.com
Business Development: partnering@ardelyx.com